ID   K562/R7
AC   CVCL_D573
SY   K-562/R7; RK562
DR   BTO; BTO_0005195
DR   ChEMBL-Cells; CHEMBL3833705
DR   PubChem_Cell_line; CVCL_D573
DR   Wikidata; Q54899417
RX   CelloPub=CLPUB00273;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 23
//
RX   CelloPub=CLPUB00273;
RA   Ginot L., Jeannesson P., Angiboust J.-F., Jardillier J.-C., Manfait M.;
RT   "Interactions of adriamycin in sensitive and resistant leukemic cells:
RT   a comparative study by microspectrofluorometry.";
RL   Studia Biophys. 104:145-153(1984).
//